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ABSTRACT 
 
Human African Trypanosomiasis (HAT) or Sleeping Sickness is fatal if untreated. Current drugs 
used for the treatment of HAT have difficult treatment regimens and unacceptable toxicity related issues. 
The effective drugs are few and with no alternatives available, there is an urgent need for the development 
of new medicines, which are safe, affordable and have no toxic effects. Here we describe different series of 
lead compounds that can be used for the development of drugs to treat HAT. 
In vivo imaging provides a fast non-invasive method to evaluate parasite distribution and 
therapeutic efficacy of drugs in real time. We generated monomorphic and pleomorphic recombinant 
Trypanosoma brucei parasites expressing the Renilla luciferase. Interestingly, a preferential testis tropism 
was observed with both the monomorphic and pleomorphic recombinants. Our data indicate that 
preferential testis tropism must be considered during drug development, since parasites might be protected 
from many drugs by the blood-testis barrier (Paper I). 
In contrast to most mammalian cells, trypanosomes cannot synthesize purines de novo. Instead 
they depend on the host to salvage purines from the body fluids. The inability of trypanosomes to engage in 
de novo purine synthesis has been exploited as a therapeutic target by using nucleoside analogues. We 
showed that adenosine analogue, cordycepin in combination with deoxycoformycin cures murine late stage 
models of African trypanosomiasis (Paper II). 
Since deoxycoformycin was shown to be a teratogen, we aimed for developing deoxycoformycin 
independent deaminase resistant cordycepin analogues that could be used as standalone drugs in treatment 
for African trypanosomiasis. We synthesized and characterized several deaminase resistant cordycepin 
analogues. 2-Fluorocordycepin (2-fCy) showed selective trypanotoxicity and resistance against adenosine 
deaminase. 2-fCy showed good in vitro preclinical profile and is a promising new lead for development of 
treatment against African trypanosomiasis (Paper III).  
In order to identify new drugs for the treatment of HAT we performed a focused screen of 5,500 
compounds for Trypanosoma brucei subsp. A number of 2-aminopyrazines/2-aminopyridines were 
identified as promising leads. Specifically, CBK201352 a 2-aminopyrazine compound was trypanotoxic for 
T. brucei. In vitro preclinical assays predicted that CBK201352 has promising pharmacokinetic parameters. 
Mice treated with CBK201352 showed complete clearance of parasites for more than 90 days. Thus, we 
show that CBK201352 and related analogs are promising leads for the development of novel treatments for 
HAT (Paper IV). 
The intracellular reducing environment of trypanosomes is maintained by a unique thiol system. 
In trypanosomes the trypanothione and trypanothione reductase (TryR) replace glutathione and glutathione 
reductase found in most other organisms. TryR is an essential enzyme for the parasite and is absent in 
mammalian cells making it an attractive drug target. We showed that ebsulfur (EbS) a small sulfur-
containing molecule is a NADPH, concentration and time-dependent irreversible inhibitor of the T. brucei 
TryR. We demonstrated that EbS or analogues disrupt the trypanothione system with a novel mechanism 
and are promising lead compounds for the development of drugs to treat HAT (Paper V). 
